<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05055934</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1314-204</org_study_id>
    <nct_id>NCT05055934</nct_id>
  </id_info>
  <brief_title>Study of the Effectiveness and Safety of SHR-1314 for Psoriatic Arthritis</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Dose Exploratory Study to Evaluate the Effectiveness and Safety of SHR-1314 Injection in Adult Subjects With Active Psoriatic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blind, multicenter, placebo-controlled Phase II clinical&#xD;
      study, consisting of a 4-week screening period, a 12-week core treatment period, a 12-week&#xD;
      maintenance treatment period, and an 8-week safety follow-up period. It is planned to include&#xD;
      111 adult subjects with psoriatic arthritis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2021</start_date>
  <completion_date type="Anticipated">January 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 23, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects achieving ACR 20 improvement at week 12</measure>
    <time_frame>at week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects who achieved ACR 50 improvement (week 12)</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects who achieved ACR 70 improvement (week 12)</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">111</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>SHR-1314 injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1314 injection</intervention_name>
    <description>SHR-1314 injection</description>
    <arm_group_label>SHR-1314 injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject voluntarily signs an informed consent form before any procedures related&#xD;
             to the research start;&#xD;
&#xD;
          2. Age ≥18 years old and ≤75 years old at the time of signing the informed consent form,&#xD;
             regardless of gender;&#xD;
&#xD;
          3. At the time of screening, it met the 2006 psoriatic arthritis classification standard&#xD;
             (CASPAR);&#xD;
&#xD;
          4. There is active PsA before randomization;&#xD;
&#xD;
          5. Have active plaque psoriasis (at least one plaque skin lesion) at the time of&#xD;
             screening, or have a history of plaque psoriasis;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Existence of any of the following medical history or comorbid diseases: drug-induced&#xD;
             psoriasis; other active inflammatory diseases or autoimmune diseases; history of organ&#xD;
             transplantation; history of lymphocytic proliferation; severe infections, etc.&#xD;
&#xD;
          2. Have received psoriatic arthritis or psoriasis drugs, such as intra-articular&#xD;
             injections, plant preparations, etc. within a certain period of time in the past.&#xD;
&#xD;
          3. Those who are allergic to the drug ingredients or excipients in this study, or are&#xD;
             allergic to other biological agents.&#xD;
&#xD;
          4. A history of alcohol abuse or illegal drug abuse in pregnant or breastfeeding women,&#xD;
             etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yashun Cui</last_name>
    <phone>17751670812</phone>
    <email>yashun.cui@hengrui.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>September 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

